Nakamoto et al found that administration of anti-human CD9 antibody to mice inoculated with a human gastric cancer cell line resulted in reduced tumor volume, increased apoptotic indexes, and decreased tumor microvessel density, suggesting that CD9 may indeed have potential as a therapeutic target[61]. This evidence concerns the gene CD9 and gastric cancer.